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T regulatory cells (Tregs) are key players in immune regulation of
both physiological and pathophysiological conditions. There are
different Treg subsets but they can be divided into two major sub-
sets: natural Tregs (nTregs) and adaptive/induced Tregs (iTregs); or
as recently named, thymic-derived Tregs (tTregs) and peripheral-
induced Tregs (pTregs), respectively. In addition, there are two
subsets (Tr1 and Th3) of FOXP3− iTregs. It is my pleasure to
introduce to our scientific community this timely research topic,
bringing 21 contributions from several groups. These articles shed
more light on the origin, differentiation, phenotype, specificity,
function, and role of the different Treg subsets in different disease
settings.
The first article by Sakaguchi’s group elegantly discusses the
recent progress of the epigenetic modifications associated with
the functional stability of Tregs (1). FOXP3 on its own is not suffi-
cient for conferring developmental and functional characteristics
of Tregs, and simultaneous induction of Treg-specific epigenetic
changes and FOXP3 expression are required for lineage specifi-
cation and functional stability of Tregs. Future studies should
focus on understanding the molecular pathways of both epigenetic
changes and FOXP3 expression to identify ways for generation and
expansion of stable Tregs for therapeutic approaches.
The next five articles improve our understanding of the differ-
ent Treg subsets. Povoleri et al. provides a comprehensive review
of the molecular signatures and induction processes, mechanisms
of action, lineage stability, and differentiating characteristics of
both thymus and peripheral FOXP3+ and FOXP3− Tregs (2).
While there are two main Treg subpopulations, a great deal of
lineage plasticity exists. Therefore, understanding mechanisms
of Treg induction, suppressive function, and lineage stability is
vital for unraveling the role of different Treg subsets in human
diseases. Currently, Treg-based therapy is considered as a feasi-
ble approach to treat human diseases, however, the optimal use
of Tregs in therapy relies on our further understanding of Treg
plasticity as well as their epigenetic/miRNA profiling. The next
article nicely reviews the phenotypic and functional differences
between tTregs and pTreg subsets, and discusses the difficulty in
distinguishing these subsets (3). While FOXP3 is a key marker
for Treg development and function, its sole expression is not use-
ful to discriminate between activated T cells, bona fide Tregs, or
even between different Treg subsets and additional markers are
required. The validity and controversy of some of the recently
identified markers, including Helios, LAP/GARP, and Neuropilin-
1, as markers of tTregs and activated Tregs, are discussed. The
review by Goldstein et al. addresses the role of three important
cytokines including IL-2, TGF-β, and TNF-α in differentiation
and homeostasis of tTregs and pTregs (4). TNF-α inhibitors indi-
cate that part of their anti-inflammatory effect could be mediated
by their action on Tregs; however, limited information is avail-
able and more work is required to understand the effect of TNF-α
on Tregs. Cytokine administration or blocking are in many clinical
trials to modulate inflammatory diseases, therefore a better under-
standing of cytokine effects on the induction and/or expansion of
Treg subsets should provide insights on improving the efficacy of
immunotherapeutic modalities. The following review focuses on
iTregs, while making comparisons to nTregs, and their function
and approaches to induce their generation in vivo and in vitro
as a promising therapeutic target (5). It is clear that more mark-
ers remain to be elucidated to accurately define iTregs. Human
autoimmune diseases are characterized by a reduction in Treg
numbers and/or function, and iTregs might have the potential
to restore tolerance to treat autoimmune diseases. The molecular
mechanisms of inducing the generation of iTregs, both in vivo and
in vitro are discussed. It is concluded that a complex of regulated
series of interactions with FOXP3 are required for establishing
Treg stability. The following review focuses on both dendritic cells
(DCs) and Tregs and the role of DCs in controlling antigen-specific
nTregs and iTregs in the periphery (6). The authors give details on
how different subsets of DCs play different roles in induction and
expansion of nTregs and iTregs. There are specialized DC subsets
in peripheral locations that act to expand nTregs or to induce the
generation of FOXP3+ iTregs from CD4+ FOXP3− T cells.
Role and function of Tregs in cancer is a major focus in this
research topic due to the important role that these cells play
in dysregulation of anti-tumor immunity. The next five articles
review our current knowledge and give us more insights on this
important topic. Adeegbe and Nishikawa comprehensively focus
on the involvement of nTregs in various animal models and human
tumors (7). They further discuss iTregs and the relationship and
cooperation with nTregs to dampen immune responses against
tumors. They provide evidences supporting the role of nTregs in
cancer with less consensus on the role of iTregs because of the lack
of their precise definition. Further understanding of the func-
tion of both iTregs and nTregs and their discrimination in each
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tumor setting will certainly help future therapeutic approaches to
eliminate or block these cells for improving anti-tumor immunity
and clinical benefits. The next comprehensive review covers the
current agreements and discrepancies on the role of tTregs and
pTregs in cancer (8). Mechanisms of Treg expansion in tumors
remain controversial because both tTreg proliferation and iTreg
generation may happen in the same tumor setting. The authors
propose innovative immunotherapeutic strategies to divert unsta-
ble/uncommitted Treg, mostly enriched in the pTreg pool, into
tumor-specific effector cells, while preserving systemic immune
tolerance mediated by self-specific tTreg. Treg levels are not only
increased in the blood of cancer patients, but they are also signifi-
cantly elevated within tumor tissues; therefore the focus of the next
review is on Tregs in the tumor microenvironment (9). It is vital to
understand the processes of Treg elevation in cancer patients and
to identify the specific mechanisms involved in their accumulation
within the tumor. These mechanisms could include chemokine-
mediated recruitment of FOXP3+ Tregs, induction of Tregs, and
proliferation of tTregs within the tumor microenvironment. Addi-
tionally, potential strategies for targeting the different mechanisms
of Treg enrichment in tumor microenvironment in attempts to
improve cancer immunotherapy are discussed. Wainwright et al.
reviews Tregs in brain cancer, providing details of their pheno-
type, mechanisms involved in their pathogenesis, and therapeutic
strategies to target these cells in brain tumor (10). The features
of brain tumors determine the nature of tumor-infiltrating Tregs.
In this particular cancer setting, the authors propose that tTregs
are the key players contributing to tumor progression and fail-
ure of immunotherapies. Indoleamine 2,3-dioxygenase 1 (IDO) is
overexpressed in brain tumor and its critical involvement in regu-
lating the levels of tumor-infiltrating Tregs is a major focus of this
article. The next review discusses the role of Tregs in cancer devel-
opment with a focus on early events following the interactions
between tumor and the immune system (11). Number and qual-
ity of Tregs recruited to the tumor microenvironment in the very
early stage have a significant impact on the outcome of anti-tumor
immunity and subsequent tumor development. The authors pro-
pose that pTregs are unlikely to have much impact in most cancers
because the fate of the tumor is being decided early, and preven-
tive vaccines against cancer should be considered while avoiding
therapeutic vaccines, as they could worsen host tolerance to tumor
antigens.
The next three articles focus on different disease settings. Beres
and Drobyski elegantly review the role of Tregs in the biology of
graft versus host disease (GVHD) (12). There is a persistent reduc-
tion in peripheral Treg levels of patients with high clinical grades of
acute GVHD, compared to patients with lower grade acute GVHD
or no GVHD. Although there has been a significant understand-
ing of the role of Tregs in GVHD, it remains unclear about the
exact role of each Treg subset (e.g., tTregs, pTregs, CD8+ Tregs)
and further studies are required. Exploiting FOXP3+ Tregs pro-
vides a promising approach to treat GVHD in patients. Preclinical
data and clinical studies using Tregs as an adoptive cellular therapy
for the prevention of GVHD in human are presented. Bluestone’s
group presents their opinion in this hypotheses and theory article
regarding the role of pTregs in immune homeostasis and autoim-
munity (13). Some cell surface markers and transcription factors,
such as Neuropilin-1 and Helios, which may distinguish tTreg from
pTreg subsets in vivo are discussed. It is proposed that pTregs have
a distinct phenotype and function from tTregs and in vitro gener-
ated Tregs. While tTregs are central to immune homeostasis and
prevention of autoimmunity, pTregs have specialized functions
depending on the type of inflammation, and they have vital roles
in certain settings such as mucosal immunity and fetal tolerance.
The next review discusses the signals that activate tTregs once
entering peripheral lymphoid tissues (14). The authors provide
evidence, mainly from their own work, and propose that tTregs
can, upon activation in the presence of antigen, become antigen-
specific Tregs with stronger suppressive capacity; this is dependent
on late Th1 and Th2 cytokines, and not the early cytokines IL-2
and IL-4.
The next three articles focus on the role of Tregs in infection.
The first article details the role of CD4+ FOXP3+ Treg subsets
in HIV infection (15). Treg quantification and function in HIV
infection remain controversial because of the lack of specific Treg
markers to identify the different human Treg subsets, in addi-
tion to the discrepancies originated from different approaches to
analyze Tregs. For a better interpretation of the role of Tregs in
HIV, both percentages and absolute Treg numbers, in addition to
the stage of HIV infection should be considered. The recent find-
ings of the existence of phenotypically and functionally distinct
human CD4+ FOXP3+ Treg subsets may provide more insights
on understanding the effect of Tregs on HIV and effect of HIV
on Tregs. In the next research article, Germanidis et al. exam-
ined liver biopsies from patients with chronic hepatitis B virus
(HBV) for the expression of different immunosuppression-related
genes (16). They report that the immunosuppressive environment
of liver is down-regulated on maintained long-term remission
in comparison with active disease. The following review sum-
marizes the different Treg subsets and their function in filarial
parasite infection (17). Although, it is agreed that chronic filarial
infection is associated with increases of most of the Treg subsets;
IL-10-mediated regulation by Tr1 cells, along with conventional
IL-10-producing Th2 cells, is the most consistent finding. Defin-
ing precise markers for the different Treg subsets should provide
more insights into understanding their role and mechanisms of
action and as potential therapeutic targets in many disease setting
including parasitic infections.
The last group of these series is categorized as four miscel-
laneous articles. Due to its pleotropic actions and great signifi-
cance in immunomodulation, Wraith’s group describes in detail,
the regulation of the adaptive immune responses by IL-10 (18).
This review focuses on IL-10 produced by FOXP3+ tTregs and
pTregs, FOXP3− pTregs, and different T helper subsets. Our bet-
ter understanding of the role of IL-10 in immunomodulation
gave the opportunity to design more efficient, antigen-specific
immunotherapies for clinical applications including allergic and
autoimmune diseases. While IL-10 and TGF-β are the most com-
monly studied immunosuppressive cytokines, the recently iden-
tified IL-35 has been shown to have potent suppressive functions
in vitro and in vivo. In this regard, Olson et al. review the struc-
ture and function of IL-35 as a key mediator of suppression of T
effector cells with the potential to propagate infectious tolerance
through the generating of potent IL-35-secreting inducible Tregs
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(iTr35) (19). The next review focuses on different iTreg-mediated
immunosuppressive mechanisms, specifically adenosine (ADO)
and prostaglandin E2 (PGE2), which can compromise anti-tumor
immune responses (20). The authors propose the significance of
ADO- and PGE2-mediated suppression in cancer patients. Phar-
macologic interventions designed to selectively target ADO and
PGE2 pathways could not only inhibit the tumor-derived factors
but also silence the suppressive activities of Tregs and thus restore
the anti-tumor activity of T effector cells. The last research arti-
cle shows that a subpopulation of CD25hiTNFR2+ cells generated
in vitro from CD4+ cells through TCR stimulation express FOXP3
and other Treg markers, but have effector functions rather than
suppressive characteristics (21).
In summary, a considerable progress has been made in under-
standing the role and function of Treg subsets in different disease
settings. Further understandings of the molecular pathways and
their mechanisms of action and defining surface markers specific
for the different Treg subsets should provide chances to use Tregs
in the clinic for treating different diseases or to target them to
enhance anti-tumor/microbial immune responses.
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